We are live on ! Find out more
TCM

Traynor Capital Management Portfolio holdings

AUM $2.18B
1-Year Est. Return 62.36%
This Fund
S&P 500
This Quarter Est. Return
+5.92%
1 Year Est. Return
+62.36%
3 Year Est. Return
+225.14%
5 Year Est. Return
+309.6%
10 Year Est. Return
+1,325.66%
AUM
$210M
AUM Growth
+$7.69M
Cap. Flow
+$4.27M
Cap. Flow %
2.03%
Top 10 Hldgs %
44.48%
Holding
178
New
16
Increased
72
Reduced
69
Closed
10

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$840K
2
AAPL icon
Apple
AAPL
+$728K
3
MO icon
Altria Group
MO
+$501K
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$439K
5
SNAP icon
Snap
SNAP
+$408K

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$516K
2
AMZN icon
Amazon
AMZN
+$363K
3
QCOM icon
Qualcomm
QCOM
+$343K
4
VMC icon
Vulcan Materials
VMC
+$287K
5
IJR icon
iShares Core S&P Small-Cap ETF
IJR
+$239K

Sector Composition

Rank Sector Weight
1 Technology 11.78%
2 Communication Services 11.14%
3 Healthcare 9.45%
4 Consumer Discretionary 7.27%
5 Industrials 5.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIG icon
151
Transocean
RIG
$5.7B
$178K 0.08%
16,809
-3,500
-17% -$30.1K
SLV icon
152
iShares Silver Trust
SLV
$28B
$178K 0.08%
+11,197
New +$178K
SIRI icon
153
SiriusXM
SIRI
$10.2B
$177K 0.08%
3,258
+1
+0% +$55
MRO
154
DELISTED
Marathon Oil Corporation
MRO
$172K 0.08%
12,784
-1,012
-7% -$12K
PGX icon
155
Invesco Preferred ETF
PGX
$3.8B
$168K 0.08%
11,181
-1,588
-12% -$24K
DNI
156
DELISTED
Dividend and Income Fund
DNI
$160K 0.08%
12,522
– –
TXMD icon
157
TherapeuticsMD
TXMD
$23.6M
$134K 0.06%
526
+70
+15% +$20.2K
WT icon
158
WisdomTree
WT
$3.21B
$111K 0.05%
+11,052
New +$107K
BGY icon
159
BlackRock Enhanced International Dividend Trust
BGY
$526M
$104K 0.05%
15,991
+112
+0.7% +$717
CHK
160
DELISTED
Chesapeake Energy Corporation
CHK
$96K 0.05%
110
-36
-25% -$30.9K
SIOX
161
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$87K 0.04%
+1,625
New +$274K
FIT
162
DELISTED
Fitbit, Inc. Class A common stock
FIT
$69K 0.03%
10,000
– –
PDLI
163
DELISTED
PDL BioPharma, Inc.
PDLI
$51K 0.02%
15,000
– –
SGYP
164
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$43K 0.02%
16,900
+4,750
+39% +$16.2K
DHY
165
Credit Suisse High Yield Credit Fund
DHY
$239M
$37K 0.02%
+12,944
New +$36.9K
SID icon
166
Companhia Siderúrgica Nacional
SID
$1.23B
$35K 0.02%
+12,800
New +$34.3K
EPE
167
DELISTED
EP Energy Corporation
EPE
$33K 0.02%
10,000
– –
SDRL
168
DELISTED
Seadrill Limited Common Stock
SDRL
$6K ﹤0.01%
68
-37
-35% -$3.23K
ALNY icon
169
Alnylam Pharmaceuticals
ALNY
$29.5B
– –
-6,479
Closed -$516K
BRW
170
Saba Capital Income & Opportunities Fund
BRW
$337M
– –
-7,401
Closed -$79K
EW icon
171
Edwards Lifesciences
EW
$51.1B
– –
-5,190
Closed -$201K
GNW icon
172
Genworth Financial
GNW
$3.76B
– –
-38,409
Closed -$132K
MKTX icon
173
MarketAxess Holdings
MKTX
$5.71B
– –
-991
Closed -$203K
QCOM icon
174
Qualcomm
QCOM
$159B
– –
-6,467
Closed -$343K
VMC icon
175
Vulcan Materials
VMC
$36.7B
– –
-2,317
Closed -$287K
4 5 6
7
8

Similar funds

SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
SCP
Seizert Capital Partners Birmingham, Michigan $2.17B AUM 11.2% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
ET
Entropy Technologies New York $2.17B AUM 21.46% 1-Year Est. Return
MMLI
Massachusetts Mutual Life Insurance Springfield, Massachusetts $2.17B AUM 48.68% 1-Year Est. Return
MIAS
Mason Investment Advisory Services Reston, Virginia $2.17B AUM 28.39% 1-Year Est. Return
ORCP
One Rock Capital Partners New York $2.19B AUM

Traynor Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Traynor Capital Management held 178 positions worth $210M, up 3.8% from $203M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Traynor Capital Management's Q3 2017 filing shows 16 new, 72 increased, 69 reduced and 10 closed positions. Its largest new stake was Teva Pharmaceuticals: 19,502 shares worth $335K. The largest sale was Alnylam Pharmaceuticals, an estimated $516K.

By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 11% a quarter earlier, followed by Communication Services and Healthcare.

  • Traynor Capital Management's largest Q3 2017 buy was Teva Pharmaceuticals: 19,502 shares worth $335K.
  • Traynor Capital Management added most to Intuitive Surgical in Q3 2017, an estimated $840K increase.
  • Traynor Capital Management's biggest Q3 2017 reduction was Amazon, cutting an estimated $363K.
  • Traynor Capital Management fully exited Alnylam Pharmaceuticals in Q3 2017, selling an estimated $516K.
  • Traynor Capital Management's ten largest holdings make up 44% of its $210M portfolio in Q3 2017.
  • Traynor Capital Management opened 16 new positions and closed 10 in Q3 2017.
  • Traynor Capital Management's portfolio value rose 3.8% quarter-over-quarter to $210M.

Based on Traynor Capital Management's 13F filing for Q3 2017, filed 27 Oct 2017.